Clinical trials: Osteopenia or Osteoporosis
Osteopenia or Osteoporosis
The Effect of Pre-exercise Feeding on Bone Turnover Biomarkers
Osteoporosis is a major contributor to loss of independence due to bone fractures and resulting hospital treatments lead to significant morbidity.
- Trial name
- NCT06550466
- Testing
- Breakfast only, FAST, FED
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sheffield Hallam University
Osteoporosis, Bone Loss, Age Related
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to…
- Conditions
- Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
- Trial name
- NCT00578981
- Testing
- Osteoporosis Choice Decision Aid
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Osteoporosis, Osteopenia
Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise
We are interested in determining if there exist a short-term response in the serum markers and hormones that participate in the regulation of bone tissue formation and breakdown to a single, high-intensity exercise session of…
- Trial name
- NCT00572871
- Testing
- plyometric exercise, resistance exercise, No exercise
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Change in Bone Mineral Density, Bone Loss
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in…
- Trial name
- NCT05303636
- Testing
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Where
- 37 sites in United States, Czechia and 1 more
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Osteopenia or Osteoporosis
Profylactic Treatment for Patients in Risk Osteoporosis
The aim is to compare the daily intake of Calsium (Ca) + vitamin D with and without daily optimal efficacy dose (OED) of Jarlsberg on Bone Mineral Density (BMD) and bone markers (BM) to Osteopeni patients (OP).
- Trial name
- PF-Jarlsberg (NCT05787808)
- Testing
- Calsium, Vitamin D, Jarlsberg cheese
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meddoc